The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| COMPASS THERAPEUTICS INC | COM | 20454B104 | 4,743 | 3,500,000 | SH | SOLE | 3,500,000 | 0 | 0 | ||
| GLOBUS MED INC | CL A | 379577208 | 7,896 | 107,024 | SH | SOLE | 107,024 | 0 | 0 | ||
| HELIX ACQUISITION CORP | COM CL A | G4444C102 | 1,521 | 137,000 | SH | SOLE | 137,000 | 0 | 0 | ||
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 12,428 | 654,108 | SH | SOLE | 654,108 | 0 | 0 | ||
| SURROZEN INC | *W EXP 08/01/203 | 86889P117 | 291 | 1,165,832 | SH | SOLE | 1,165,832 | 0 | 0 | ||
| SURROZEN INC | COM | 86889P109 | 10,527 | 3,497,500 | SH | SOLE | 3,497,500 | 0 | 0 | ||
| TANDEM DIABETES CARE INC | COM NEW | 875372203 | 17,133 | 147,327 | SH | SOLE | 147,327 | 0 | 0 | ||
| UNITED THERAPEUTICS CORP DEL | COM | 91307C102 | 4,407 | 24,563 | SH | SOLE | 24,563 | 0 | 0 | ||